YIH
LGND icon

Y-Intercept (HK)’s Ligand Pharmaceuticals LGND Stock Holding History

Y-Intercept (HK)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,115
Closed -$542K – 1368
2022
Q4 		$542K Buy
+8,115
New +$528K 0.08% 409

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Y-Intercept (HK)'s LGND Position: Q1 2023 in Review

Y-Intercept (HK) sold out of Ligand Pharmaceuticals (LGND) in Q1 2023, closing a stake of 8,115 shares — an estimated $542K sold.

Y-Intercept (HK) first reported a position in LGND in Q4 2022 and held it in 1 quarter. The position peaked at $542K in Q4 2022. 212 funds tracked by Wall St. Rank hold LGND as of Q1 2023.

  • Y-Intercept (HK) reported no remaining Ligand Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Y-Intercept (HK) sold 8,115 Ligand Pharmaceuticals shares in Q1 2023, an estimated $542K.
  • Y-Intercept (HK) first reported a position in Ligand Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Y-Intercept (HK)'s Ligand Pharmaceuticals position peaked at $542K in Q4 2022.
  • 212 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2023.

Based on Y-Intercept (HK)'s 13F filing for Q1 2023, filed 9 May 2023.